期刊文献+

血清神经生长因子与髓鞘碱性蛋白和血清炎症因子在精神分裂症患者中的表达水平及相关性分析

Expression levels and correlation analysis of serumnerve growth factor and myelin basic protein and seruminflammatory factors in patients with schizophrenia
下载PDF
导出
摘要 目的探讨血清神经生长因子(NGF)、髓鞘碱性蛋白(MBP)及血清炎症因子在精神分裂症患者中的表达水平及相关性分析。方法选取2019年1月至2022年1月聊城市第四人民医院收治的78例精神分裂患者作为观察组,另选取同期74例健康体检者作为对照组。比较两组NGF、MBP及炎症因子[白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、白细胞介素-12(IL-12)]水平、认知功能评分,采用Pearson直线相关分析各指标水平与阳性和阴性症状量表(PANSS)总分的相关性。结果观察组NGF水平明显低于对照组,MBP、IL-1β、IL-6、IL-12水平均明显高于对照组,差异有统计学意义(P<0.05)。观察组范畴流畅性(CF)、简明精神分裂症认知评估-符号编码测验(BACS-SC)、普金斯词语学习测验修订版(HVLT-R)、韦氏记忆量表-第三版:空间广度(WMS-ⅢSS)、神经心理成套测验(NAB)、简易视觉空间记忆测验修订版(BVMT-R)评分均明显低于对照组,连线测验(TMT)评分高于对照组,差异有统计学意义(P<0.05)。Pearson相关性分析结果显示,NGF水平与PANSS总分呈负相关(r<0,P<0.05),MBP、IL-1β、IL-6、IL-12水平与PANSS总分呈正相关(r>0,P<0.05)。结论NGF水平在精神分裂患者中呈低表达,与临床症状呈负相关关系;MBP及炎症因子在精神分裂患者中呈高表达,与临床症状呈正相关关系,可在临床作为辅助诊断依据。 Objective To investigate the expression levels and correlation analysis of serum nerve growth factor(NGF),myelin basic protein(MBP)and serum inflammatory factors in patients with schizophrenia.Methods 78 patients with schizophrenia admitted to the Liaocheng Fourth People's Hospital from January 2019 to January 2022 were selected as the observation group,and 74 healthy subjects were selected as the control group during the same period.The levels of NGF,MBP,inflammatory factors(interleukin-1β[IL-1β],interleukin-6[IL-6],interleukin-12[IL-12])and cognitive function scores were compared between the two groups,Pearson linear correlation analysis was used to analyze the correlation between the levels of each indicator and the total score of positive and negative symptom scale(PANSS).Results The level of NGF in the observation group was significantly lower than that in the control group,and the levels of MBP,IL-1β,IL-6 and IL-12 were significantly higher than those in the control group,the differences were statistically significant(P<0.05).The category fluency(CF),brief assessment of cognitionin schizophrenia-symbol cod-ing(BACS-SC),Hopkins verbal learning test-revised(HVLT-R),Wechsler memory scale-third edition spatial span(WMS-ⅢSS),neuropsychologi-cal assessment battery(NAB)and brief visuospatial memory test-revised(BVMT-R)scores in the observation group were significantly lower than those in the control group,and trail making test(TMT)scores were higher than those in the control group,the differences were statistically significant(P<0.05).The results of Pearson correlation analysis showed that NGF levels was negatively correlated with the total score of PANSS(r<0,P<0.05),while the MBP,IL-1β,IL-6,IL-12 levels were positively correlated with the total score of PANSS(r>0,P<0.05).Conclusion The level of NGF is low in schizophrenic patients and is negatively correlated with clinical symptoms,the levels of MBP and inflammatory factors are highly ex-pressed in patients with schizophrenia and are positively correlated with clinical symptoms,which can be used as auxiliary diagnostic basis in clinic.
作者 马书玉 谭博 王志远 MA Shuyu;TAN Bo;WANG Zhiyuan(Department of Clinical Laboratory,Liaocheng Fourth People's Hospital,Liaocheng,Shandong,252000,China)
出处 《当代医学》 2024年第4期90-93,共4页 Contemporary Medicine
关键词 血清生长因子 髓鞘碱性蛋白 炎症因子 精神分裂症 相关性分析 Serum growth factor Myelin basic protein Inflammatory factor Schizophrenia Correlation analysis
  • 相关文献

参考文献15

二级参考文献131

  • 1黎氏水,谈勇.礞石滚痰丸加减治疗更年期抑郁症举隅[J].甘肃中医,2005,18(5):11-12. 被引量:3
  • 2中风病诊断与疗效评定标准(试行)[J].北京中医药大学学报,1996,19(1):55-56. 被引量:5920
  • 3胡海燕,朱未名,郑虹.礞石涤痰汤结合西药治疗精神分裂症临床对照研究[J].中医杂志,2007,48(2):129-131. 被引量:21
  • 4Gold JM. Cognitive deficits as treatment targets in schizophrenia [J] . Schizophr Res, 2004, 72:21-28.
  • 5Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agentsfor the treatment of cognitive impairments in schizophrenia [J]. Schizophr Bull, 2007, 33: 1120-1130.
  • 6Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder [ J ] . J Clin Psychiatry, 2006, 67: 12.
  • 7Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials [ J ] . Schizophr Res, 2004, 72 : 1 - 3.
  • 8Nuechterlein KH, Green MF, Kern RS, et al. The MAT- RICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity [ J ] . Am J Psychiatry, 2008, 165: 203-213.
  • 9Kern RS, Nuechterlein KH, Green MF, et al. The MAT- RICS Consensus Cognitive Battery, part 2: co-norming and standardization [ J ] . Am J Psychiatry, 2008, 165: 214 - 220.
  • 10Green MF, Nuechterlein KH, Kern RS, et al. Functional co-primary measures for clinical trials in schizophrenia: resuits from the MATRICS Psychometric and Standardization Study [J] . Am J Psychiatry, 2008, 165:221-228.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部